1 Min Read
* ANNOUNCES CE-IVD MARKING OF MIRPREDX 31-3P KIT
* TEST PREDICTS PATIENT RESPONSE TO ANTI-EGFR THERAPY IN RAS WILD-TYPE METASTATIC COLORECTAL CANCER Source text for Eikon: Further company coverage: (Gdynia Newsroom)
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2018 Reuters. All Rights Reserved.